AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfront. The bolt-on deal, which ...
101.5 x 127 cm. (40 x 50 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback